TrialCancer2020

NRG/RTOG 1122: A phase 2, double-blinded, placebo-controlled study of bevacizumab with and without trebananib in patients with recurrent glioblastoma or gliosarcoma.

Eudocia Q Lee et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.